Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.
In the past week, Evaxion Biotech entered a partnership regarding a vaccine against gonorrhea, Ascendis Pharma presented results of a trial with TransCon, and ViroGates announced positive results from a clinical trial suPAR-guided antibiotec treatment in sepsis.
The past week was another week full of exciting news with 8 of the 20 listed Danish biotech companies publishing news. 11 of the 20 companies had a positive share price development the past week and 8 companies have a positive share price performance year to date. Cessatech continues to be the best performing stock year-to-date.
Company news the past week
Ascendis Pharma
Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency (Link)
Biosergen
No news the past week
Cessatech
Cessatech announces last participant dosed in pivotal trial 0205 with lead candidate CT001 (Link)
No news the past week
No news the past week
Evaxion Biotech
Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company (Link)
Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea (Link)
Expres2ion
Last day of trading in warrants of series TO 8 in Expres2ion Biotechnologies 18 September 2023 (Link)
Fluoguide
No news the past week
Genmab
No news the past week
Gubra
No news the past week
Initiator Pharma
Initiator Pharma announces indication expansion – clinical drug candidates active in models of female sexual dysfunction (Link)
IO Biotech
No news the past week
Pila Pharma
No news the past week
Saniona
No news the past week
Scandion Oncology
No news the past week
SynAct Pharma
No news the past week
ViroGates
ViroGates announces positive results from a randomized controlled clinical trial on suPAR-guided antibiotic treatment in sepsis presented today at the European Shock Conference in Vienna, Austria (Link)
Zealand Pharma
Zealand Pharma A/S – admittance to trading and official listing of new shares due to exercise of employee warrants (Link)
Y-mAbs Therapeutics
Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology (Link)
2cureX
No news the past week
SELECTED CASES
SHARE PRICE DEVELOPMENTS
On average, the Danish biotech stocks delivered a positive share price performance last week of 4.8%. Biosergen rose 77% without even announcing any news. ViroGates followed with a 24% increase after announces positive results from a randomized controlled clinical trial on suPAR-guided antibiotic treatment in sepsis. Notably, Evaxion only rose 4% after expanding preclinical bacterial pipeline with a leading pharmaceutical company as well as entered a partnership to develop a vaccine against gonorrhea. On the other hand, Ascendis Pharma fell the most with a 7% decrease following results of a trial with TransCon. The best stocks year-to-date include Curasight, Cessatech Fluoguide, and Saniona after soaring 87-154%. Overall, the Danish biotech stocks are in positive terrotory this year with a year-to-date return of 3.3%. However, it is driven by the few companies delivering very positive returns.
Read more about Curasight (in Danish): Et succesfuldt kvartal for Curasight med mere i vente
Overview of share price developments the past week, year-to-date and last twelve months
